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Abstract 
Pharmacogenetic testing is increasingly implemented in routine diagnostics. However, quality 
control measures, in particular confirmation practices e.g. the use of two independent genotyping 
techniques, are subject of debate and there are no clear guidelines. The aim of the current paper is 
to discuss the current practice in confirmation testing in the field of pharmacogenetics and draw 
attention to this situation. DPYD genotyping is used as a case example to highlight the importance of 
assigning the correct genotype. Current confirmation practices in laboratories are explored through 
a survey. Substantial heterogeneity was observed with 54% of the laboratories applying different 
forms of confirmation practice. Finally, we evaluated over 10 years of genotyping results from two 
large genotyping facilities, which both use a second, independent genotyping technique. 
Discrepancies between tests were identified in 9 patients (0.01%), possibly due to allele dropout. We 
feel that a second, independent technique is useful for genetic tests with a high clinical impact, such 
as DPYD testing. Guidelines can help to align confirmatory laboratory practices for 
pharmacogenetics, which may need to be specified per gene and test. 
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1. Introduction  
Over the past ten years, our knowledge of pharmacogenetics (PGx) has increased significantly. With 
decreasing assay costs, availability of PGx dosing guidelines and inclusion of PGx information in drug 
labels PGx testing has become an attractive strategy for routine diagnostics [1]. For some diseases 
and drugs (pharmaco)genetic testing to predict therapeutic response is already widely accepted in 
clinical practice (e.g. lung cancer and EGFR status) or even mandatory (e.g. abacavir and HLA-B*5701 
allele carriers) [2]. For a limited number of (pharmaco)genetic tests approval of the Food and Drug 
Administration (FDA) is available, e.g. CYP2D6 (Luminex) and INFINITI CYP2C19 assays, possibly 
increasing its use in clinical care [3-5]. The Roche AmpliChip for cytochrome p450 CYP2D6 and 
CYP2C19 (Roche Molecular Diagnostics, Pleasanton, CA, USA) was the first FDA approved (December 
24th, 2004) and commercially available PGx test [6]. If no FDA-approved assay is available, laboratory 
developed tests (LDTs) can be used [7].  
 
Many laboratories use LDTs. It is important to have quality assurance of the PGx test results from 
these LDTs, which can be achieved by participating in a proficiency testing program. Proficiency 
testing programs are regulated by independent organizations, such as the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC) [8], the German Reference Institute for 
Bioanalytics (RfB) [9], the European Molecular Genetics Quality Network (EMQN) in the UK [10], or 
the Dutch Foundation for Quality Assessment in Medical Laboratories (SKML) [11]. In addition, the 
Genetic Testing Reference Material Coordination Program (GeT-RM) was set-up to guard quality 
assurance, assay development, validation and proficiency testing [12]. Another less commonly 
applied quality control measure used by laboratories to ensure quality of PGx test results is 
confirmation practice, e.g. the use of two independent genotyping techniques. However, these 
measures have disadvantages, such as increased costs and labour, and are subject of debate. It is yet 
unknown if  differences in laboratory practices exist as there are no clear guidelines on this 
particular quality control aspect.  
 
The aim of the current paper is to discuss the current practice in confirmation testing in PGx and 
draw attention to this situation. We first assess current confirmation practices to assure the validity 
of PGx test results, by means of a questionnaire using DPYD genotyping as an impactful case. 
Secondly, we evaluate genotyping results from Leiden University Medical Center (LUMC) and 
Erasmus Medical Center Rotterdam (Erasmus MC), where two independent genotyping methods are 
applied to confirm results.  
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2. Importance of analytical validity and assigning the correct genotype 
The number of executed PGx tests is rapidly increasing, partly due to incorporation of PGx 
information in drug labels -currently over 260- some of them strongly suggesting or demanding a 
priori PGx testing (e.g. abacavir, clopidogrel, eliglustat) [13]. For some other diseases or drugs, which 
have a (pharmaco)genetic application available, the use in clinical practice remains limited and is 
subject to debate (e.g. bupropion, tamoxifen) [1, 14]. By contrast to many other clinical laboratory 
tests, a (pharmaco)genetic test is usually performed only once in the lifespan of a patient. As a 
result, it is of utmost importance that the correct result is reported. Consequences of a false positive 
or false negative result could be fatal, as is explained in the following example of DPYD genotyping 
for fluoropyrimidines (5-fluorouracil/5-FU, and capecitabine) [15]. There is compelling evidence on 
the reduction of severe fluoropyrimidine-induced toxicity when using prospective PGx for four DPYD 
variants, and dosing recommendations for these four DPYD variants have been published by the 
Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics 
Working Group (DPWG) [16-19]. Despite this, clinical implementation is not yet part of routine 
clinical care in many hospitals [20]. When exposed to standard dosages of fluoropyrimidines, carriers 
of a DPYD variant are at high risk for severe, or even fatal, toxicity. Despite the low frequency of 
DPYD variants, prospective genotyping for DPYD variants in all patients prior to initiating 
fluoropyrimidine treatment was shown to be cost-saving [21]. Thus, it is safer, but not more 
expensive to genotype patients. Misclassification of the DPYD genotype can result in suboptimal 
therapy (false positive) or even have lethal consequences from fluoropyrimidine treatment in 
standard dosages (false negative). In addition, therapeutic drug monitoring (TDM) could be used to 
monitor the 5-FU dose during treatment, but is rarely executed. For capecitabine, the oral pro-drug 
of 5-FU, TDM protocols need to be developed. This particular example shows the clinical importance 
and substantial consequences of PGx testing and illustrates why it is of utmost importance to report 
the correct result.  
 
3. The dilemma 
Laboratories apply different genotyping techniques to generate PGx results. Sanger sequencing 
remains the gold standard for DNA sequencing [22], even though this can be prone to errors [23]. In 
general, PCR-based assays (including Sanger sequencing) are considered a robust methodology with 
reliable results. Each assay is subjected to extensive validation by the company or laboratory to 
reduce the risk of a priori errors. However, after the implementation of a test in clinical practice, it is 
still possible to have false positive or false negative results, e.g. due to allele dropout [24]. Allele 
dropout can be caused by a newly acquired variant located at the site of a primer, causing the 
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binding of this primer to fail. A genetic variant located on that DNA strand will not be genotyped, 
and the patient is misclassified as homozygous carrier of the variant on the other strand. 
 
To mitigate the risk of allele dropout a laboratory can use a second, independent method that uses 
different primers to confirm results. However, this results in increased costs, labour and turn-
around-time. Should laboratories execute a second method to confirm results, or not? The dilemma 
of the quality control aspect of PGx testing is based on the probability of a genotyping error to occur, 
the level of increased effort and costs to detect the error and the consequence of not detecting the 
error. A genotyping error, e.g. due to allele dropout, can be detected by a second, independent 
genotyping assay, which is the most adequate, but comprehensive, available method. Abolishing a 
second method or repetition can thus save both time and costs, possibly increasing the likeliness of 
use of PGx testing since cost-effectiveness is often reported as a barrier for implementing PGx 
testing [15]. The consequence of an error in PGx can be substantial, yet it is unrealistic to aim to 
never have an incorrect result. This dilemma is why differences in confirmation practices in 
laboratories could exist and why guidelines are required to align laboratory practices. These 
differences could be overcome by clear guidelines from regulatory authorities, however, 
notifications from regulatory authorities are also not conclusive about this dilemma. In January 
2017, the FDA discussed that regulatory aspects on the quality control of LDTs are still under debate 
[25]. In Europe, guidelines on good pharmacogenomics practice (GPP) by the European Medicines 
Agency (EMA) issued in September 2018 include a chapter on quality aspects on PGx analyses. They 
describe the importance of proper validation prior to using genetic tests in clinical trials or a 
diagnostic setting and the detection of respective allele-drop-outs, as primer-based technologies are 
prone for these artefacts. However, no specific standpoint is taken regarding the use of a second, 
independent technique [26]. Also, the In Vitro Diagnostic Regulation (IVDR) of the European 
Parliament and of the Council on in vitro diagnostic medical devices has recently been updated and 
will come into force in 2022. Yet, these guidelines do not explicitly state what actions to guarantee 
quality are required in the laboratory. 
 
4.Confirmation practice 
4.1 Current confirmation practice in laboratories 
In order to investigate the consequences of the lack of clear guidelines we assessed the current 
confirmation practices of laboratories. A short questionnaire comprising three general questions on 
DPYD genotyping and confirmation practices in the laboratory was sent to laboratories in Europe 
and the Netherlands participating in the proficiency testing program of the RfB and SKML, 
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respectively. Details on the set-up of the questionnaire can be found in the Supplementary 
Material. Out of the 475 laboratories, 35 completed the questionnaire. One laboratory participated 
in both the European (RfB) and Dutch (SKML) questionnaire. 28 laboratories executed genotyping 
tests. Of all laboratory techniques, the TaqMan assay and melting curve analyses were most 
frequently used. A large variation between laboratories in confirmation practice was observed. 
Almost half of the laboratories did not execute a second test (either independent or repetition).  
 
4.2 Two independent genotyping methods as confirmation practice 
In addition, we assessed the impact of confirmation methods in PGx. At LUMC and the IFCC PGx 
reference laboratory at Erasmus MC, the most elaborate confirmation method, executing two 
independent genotyping tests using two different platforms, are used. We evaluated over 10 years 
of aggregated genotyping data of these two large genotyping laboratories performing duplicate 
analyses on two independent platforms. Details of the two laboratories can be found in the 
Supplementary Material. In total, 89.842 duplicate tests were executed for patient care in over 10 
years of genotyping. Nine discrepancies (0.01%) between tests were observed. One discrepancy in 
CYP3A5*3 was the result of chimerism due to allogeneic hematopoietic stem cell transplantations, 
which resulted in the determination of the genotype of both patient and donor [27, 28]. Four 
discrepancies in CYP3A5*3, one discrepancy in DPYD*13 and three discrepancies in CYP2D6*6 were 
identified, possibly due to allele dropout. The probability of finding a discrepant result when using 
two independent techniques according to our data was calculated to be 0.01%.  
 
5. Discussion 
The topic of confirmatory testing in the rapidly growing field of PGx deserves attention. At this 
moment, there are no clear guidelines on the required confirmation practice aspects of PGx testing. 
Should laboratories execute a second method to confirm results, or not? The FDA is  in debate on 
this dilemma and the current guidelines of the EMA are not very precise on the use of confirmation 
methods. Our supporting data show that there is great heterogeneity between laboratories in 
confirmation practice. Discrepant results were identified between two tests in about 0.01% of 
samples.  
Our data show a substantial variation of approaches for DPYD genotyping used in laboratories across 
Europe as well as a limited use of second, independent techniques as a confirmation method to 
assure the correctness of genotyping results. Almost half of the responders do not apply any of the 
suggested confirmation or replication methods, and implies the need for centrally organized 
guidelines. We selected DPYD as an example for its clinical relevance, as a false negative result or 
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misclassification can have a fatal outcome. The number of centres which routinely test for DPYD is 
relatively low and it is possible that a questionnaire focussing on a gene that is more commonly 
tested would have resulted in a higher response rate. However we do not expect major differences 
in confirmation practice between genes within a laboratory. 
 
To assess the usefulness of applying two independent genotyping techniques for confirmatory 
testing we evaluated genotyping results of almost 90.000 samples tested in two laboratories in over 
10 years of genotyping. We identified nine discrepant results (0.01%) between the two independent 
genotyping techniques. One discrepant result was caused by chimerism following allogeneic 
hematopoietic stem cell transplantations, and is thus not due to analytical failure. To prevent this 
particular type of error, a check-box for “transplantation patient” was added to the genotyping 
request form. Two other stem cell transplantation patients were correctly genotyped after the 
check-box was added. For the other eight samples, misclassification due to allele dropout was the 
most probable cause of the discrepancies. In this study, a frequency of 0.01% of misclassification was 
shown, whereas previous publications show higher frequencies of misclassification (0.27% in 365 
patients, Scantamburlo et al. [29] and 0.44% in 30.769 genotypes, Blais et al. [24]). A difference in 
discrepant results between the two genotyping centres was identified and might be explained by the 
different genotyping techniques used in each centre, as the call rate and accuracy of the techniques 
can be different. Additionally, CYP2D6 data of one centre was not included, as this centre did not use 
a second, independent genotyping platform to confirm genotyping results for CYP2D6. CYP2D6 is a 
highly polymorphic gene and CYP2D6-assays could be more prone to allele dropout. 
 
Another important aspect to consider is that allele dropout is test specific: it depends on the 
positions of variants and the primer positions of the assay. Therefore, caution should be taken in 
generalizing our results. Specific quality control analyses per assay may be warranted. One could 
envision for example a minimum amount of samples to be tested to show that allele dropout for 
that particular assay and primers is low, possibly as a requirement for diagnostic companies to 
demonstrate. This brings along a second important consideration, which is that the sensitivity of 
detecting allele dropouts is directly proportional to the amount of heterozygotes present. In other 
words, discrepancies for CYP2D6*4 (allele frequency 23% [30]) will be detected much earlier than 
discrepancies for, e.g. CYP2D6*7 (allele frequency 0.05% [30]). In this aspect, the determined 
discrepancy rate of 0.01% might actually be higher for specific variants.  In addition, the tests in this 
study were mainly executed in patients with a Caucasian ethnic background. As frequencies of 
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genetic variants can vary between different ethnic populations, results could be different in another 
population. 
 
The large number of genotyping test results is a strength of this study. However, specific allele 
dropout will depend on the number of samples with a particular variant. The low discrepancy rate 
shows high concordance and robustness of the methods used. As described before, the 
consequence of a misclassified genotype can be substantial, resulting in either underdosing or 
overdosing, sub sequentially leading to inefficacy or, potentially lethal, toxicity (e.g. DPYD 
genotyping). We expect that next generation sequencing (NGS) might replace some of the current 
assays in the upcoming years. NGS is also subject to allele dropout as it is PCR based, but possibly 
less compared to current techniques. This is caused by the fact that NGS has multiple coverage 
depth of the same variants, thus a failed reaction of one primer will not directly results in a 
misclassification of the variant.   
 
Differences exist between laboratories in which DPYD variants are genotyped, or they might not 
genotype for DPYD variants at all. This could have great impact on patient care as DPD phenotypes 
might be predicted differently between laboratories. The impact could be greater compared to the 
impact due to differences between laboratories in confirmation practice as quality control of these 
tests. This also accounts for other variants in other genes, and for the fact that not all associated 
variants per gene are discovered yet. Besides assay errors, human errors (switch of samples) might 
also occur. However, this discussion is out of the scope of this paper, were we focus on the dilemma 
of confirmation practice. 
 
6. Conclusions 
We have shown substantial variability between laboratories in the use of a second confirmatory 
technique for PGx testing. The risk of a discrepancy may differ between assays and the clinical 
implications will depend on the gene tested. Therefore we feel that a second, independent 
technique is useful for genetic tests with a high clinical impact, such as DPYD testing. Guidelines can 
help to align confirmatory laboratory practices for PGx, however, they may need to be specified per 
gene and per test. 
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Highlights: 
 The analytical validity of a pharmacogenetic test result is of utmost importance 
 A measure to assure analytical validity is the use of a second confirmation method 
 Heterogeneity in confirmation practice exists between laboratories 
 Guidelines are key to align laboratory practices for pharmacogenetic testing 
 Guidelines may need to be specified per gene and test 
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